Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial.

Nuccia MoriciGianMarco PoddaSimone BirocchiLuca BonacchiniMarco MerliMichele TrezziGianluca MassainiMarco AgostinisGiulia CariotiFrancesco Saverio SerinoGianluca GazzanigaDaniela BarberisLaura AntoliniMaria Grazia ValsecchiMarco Cattaneo

Published in: European journal of clinical investigation (2021)

No DVT developed in COVID-19 patients hospitalized in general wards, independently of enoxaparin dosing used for thromboprophylaxis. Pulmonary artery occlusions developed only in the o.d. group. Our trial is underpowered and with few events.

Keyphrases

venous thromboembolism
pulmonary artery
sars cov
coronary artery
direct oral anticoagulants
pulmonary hypertension
pulmonary arterial hypertension
coronavirus disease
respiratory syndrome coronavirus
study protocol
clinical trial
phase iii
phase ii